About
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.
Current Value
$66.251 Year Return
Current Value
$66.251 Year Return
Key Details
Market Cap
$12.87B
P/E Ratio
30.68
1Y Stock Return
-22.34%
1Y Revenue Growth
17.35%
Dividend Yield
0.00%
Price to Book
2.3
Strategies that include BMRN
Double maintains 5 strategies that include BMRN - BioMarin Pharmaceutical, Inc.
Growth Stocks
High risk
$5.2K
Growth Stocks focuses on companies with strong growth prospects, often found in sectors driving innovation and technological advancement. This ETF invests in companies demonstrating robust revenue and earnings growth, including technology giants, healthcare innovators, and consumer discretionary leaders.
Top Sector
Information Technology
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
178
USA Mid-Cap Companies
Medium risk
$3.8K
Targeting mid-sized U.S. companies, striking a balance between growth potential and stability. Investing in sectors like industrials, technology, consumer goods, and healthcare, it offers exposure to companies with established market positions and growth opportunities.
Top Sector
Industrials
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
316
Health Care Sector
Medium risk
$14.0K
This Strategy focuses on healthcare companies, including pharmaceuticals, biotechnology, healthcare providers, and medical equipment firms. Offering exposure to a sector driven by demographic trends and ongoing medical advancements, it's a strategic choice for investors considering healthcare's long-term growth potential.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
346
US 1000
Medium risk
$33.0K
This strategy tracks a market-cap-weighted index of the 1000-largest US companies. It offers broad exposure to the US equity market, encompassing a diverse range of sectors and industries. By investing in this fund, you gain access to the performance of large and well-established companies within the US economy.
Top Sector
Information Technology
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
1000
US Mid Cap
Medium risk
$5.0K
This strategy tracks a market-cap-weighted index of mid-cap US companies. This strategy offers targeted exposure to the growth potential of mid-sized businesses within the US market. With a diversified portfolio of holdings, it provides investors with a comprehensive approach to capturing the mid-cap segment's performance.
Top Sector
Industrials
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
401
Stock's related to BMRN
The stocks that are correlated to BMRN - BioMarin Pharmaceutical, Inc. are IONS, ITOS, KRYS, IDYA, REGN
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| 35.73% | $4.53B | -33.41% | 0.00% | |
| 34.66% | $217.71M | -54.18% | 0.00% | |
| 31.04% | $5.13B | -0.20% | 0.00% | |
| 30.66% | $1.36B | -62.39% | 0.00% | |
| 30.16% | $66.76B | -34.83% | 0.00% | |
B BRKRBruker Corp. | 29.20% | $5.71B | -58.05% | 0.56% |
| 28.94% | $1.21B | +53.20% | 0.00% | |
| 28.13% | $758.88M | -58.48% | 0.00% | |
Z ZUMZZumiez, Inc. | 28.05% | $262.48M | -3.25% | 0.00% |
| 27.88% | $2.80B | -49.80% | 0.00% | |
G GMABGenmab A/S | 27.77% | $12.23B | -35.11% | 0.00% |
| 27.72% | $29.57B | -29.70% | 0.00% | |
L LLYEli Lilly & Co. | 26.87% | $748.05B | +2.74% | 0.71% |
| 26.81% | $300.49M | -32.93% | 5.02% | |
| 26.50% | $43.36M | -84.78% | 0.00% | |
| 26.42% | $545.16M | -31.38% | 0.00% | |
| 26.40% | $1.64B | -43.30% | 0.00% | |
T TXTTextron, Inc. | 26.30% | $12.14B | -29.98% | 0.13% |
| 26.28% | $713.23M | -72.41% | 0.00% | |
| 26.27% | $181.24M | -17.45% | 2.35% | |
ETF's related to BMRN
The ETFs that are correlated to BMRN - BioMarin Pharmaceutical, Inc. are BBH, PBE, IBB, FBT, XBI
Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| 40.31% | $362.92M | 0.35% | |
| 40.19% | $229.13M | 0.58% | |
| 39.52% | $5.70B | 0.45% | |
| 36.88% | $1.09B | 0.56% | |
X XBISPDR Biotech ETF | 35.35% | $5.06B | 0.35% |
| 34.94% | $48.48M | 0.5% | |
| 34.56% | $16.30B | 0.09% | |
| 33.94% | $2.68B | 0.084% | |
| 33.78% | $3.17B | 0.39% | |
| 32.76% | $3.28B | 0.15% | |
| 32.71% | $3.91B | 0.41% | |
| 32.61% | $623.79M | 0.39% | |
| 31.96% | $37.96B | 0.09% | |
| 31.82% | $790.48M | 0.4% | |
| 31.64% | $22.41M | 0% | |
| 31.49% | $2.25B | 0.25% | |
| 31.32% | $14.37M | 0.25% | |
| 31.16% | $87.80M | 0% | |
| 31.14% | $761.54M | 0.25% | |
| 31.08% | $178.38M | 0% | |
News
SeekingAlpha
BioMarin Pharmaceutical Inc. has advancements in phenylketonuria treatment. Click to learn how Palynziq's success could expand BMRN's market in 2025.
Yahoo
Based on the late-stage data, BioMarin plans to submit a regulatory filing for expanding the label of its PKU drug Palynziq in adolescents before this year's end.
Yahoo
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen (NASDAQ:AMGN).
Yahoo
Later this year, the company plans to submit detailed outcomes from this trial to health authorities.
Yahoo
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released topline data from the Phase 3 PEGASUS trial evaluating Palynziq (pegvaliase-pqpz) compared to diet alone in 55 adolescents aged 12-17 with phenylketonuria (PKU). PKU is a rare, inherited metabolic disorder that prevents the body from breaking down the amino acid phenylalanine. Untreated phenylketonuria can lead to brain damage, intellectual disabilities, behavioral symptoms or seizures. The primary endpoints are the changes in blood Phe concent
Yahoo
We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against other most profitable biotech stocks to buy right now. With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry […]
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
0% Expense Ratios with TLH
We offer over 50 indexes with zero expense ratios.
Registration will take about 10 seconds